Hemostemix (CVE:HEM) Reaches New 1-Year Low – Here’s Why

Hemostemix Inc. (CVE:HEM) shares reached a new 52-week low during trading on Thursday . The company traded as low as C$0.08 and last traded at C$0.09, with a volume of 12750 shares changing hands. The stock had previously closed at C$0.09.

Hemostemix Stock Performance

The company’s 50-day moving average price is C$0.09 and its 200 day moving average price is C$0.09. The stock has a market capitalization of C$16.96 million, a PE ratio of -3.33 and a beta of 0.80. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.